Pharmacotherapy for benign prostatic hyperplasia — the potential for α1‐adrenoceptor subtype‐specific blockade

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|81|S1|34-47

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.81, Iss.S1, 1998-03, pp. : 34-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Apoptotic and Proliferative Index after Alpha-1-Adrenoceptor Antagonist and/or Finasteride Treatment in Benign Prostatic Hyperplasia

By  

Urologia Internationalis, Vol. 69, Iss. 4, 2002-11 ,pp. : 287-292

Karger

Access to resources Recommend Favorite

Benign Prostatic Hyperplasia: Correlations between Receptor Density and Binding Affinity of α1-Adrenoceptors and Several Clinical Parameters

By  

Urologia Internationalis, Vol. 68, Iss. 4, 2002-05 ,pp. : 246-250

Karger

Access to resources Recommend Favorite

Clinical Characteristics of α-Blocker Responders in Men with Benign Prostatic Hyperplasia

By  

Urologia Internationalis, Vol. 68, Iss. 4, 2002-05 ,pp. : 237-242

Karger

Access to resources Recommend Favorite

Seminal Plasma Prostate-Specific Antigen Level in Benign Prostatic Hyperplasia

By  

Urologia Internationalis, Vol. 72, Iss. 4, 2004-05 ,pp. : 332-334

Karger

Access to resources Recommend Favorite

Comparison of Chromogranin A, Insulin-Like Growth Factor 1 and Prostate-Specific Antigen Serum Markers in Prostate Adenocarcinoma and Benign Prostatic Hyperplasia

By  

Urologia Internationalis, Vol. 80, Iss. 1, 2008-01 ,pp. : 68-73

Karger

Access to resources Recommend Favorite